Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis
Toby M. Maher, Christina Schlecker, Doreen Luedtke, Sebastian Bossert, Donald F. Zoz, Armin Schultz
Source: ERJ Open Res, 8 (4) 00240-2022; 10.1183/23120541.00240-2022
  
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Toby M. Maher, Christina Schlecker, Doreen Luedtke, Sebastian Bossert, Donald F. Zoz, Armin Schultz. Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis. ERJ Open Res, 8 (4) 00240-2022; 10.1183/23120541.00240-2022
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|